ECONOMIC EVALUATION OF BENDAMUSTINE PLUS RITUXIMAB IN THE FIRST-LINE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
May 1, 2016, 00:00 AM
10.1016/j.jval.2016.03.1063
https://www.valueinhealthjournal.com/article/S1098-3015(16)01131-1/fulltext
Section Title :
Systemic Disorders/Conditions - Cost Studies
Section Order :
911
First Page :
A248
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)01131-1&doi=10.1016/j.jval.2016.03.1063